Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies
Portfolio Pulse from
Johnson & Johnson is in talks to acquire Intra-Cellular Therapies for $10 billion, marking a significant move in the biotech sector.
January 13, 2025 | 9:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies is in acquisition talks with Johnson & Johnson for $10 billion, which could significantly impact its valuation and market presence.
The potential acquisition by JNJ would likely lead to a significant increase in ITCI's stock price due to the premium typically paid in such deals.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Johnson & Johnson is considering a $10 billion acquisition of Intra-Cellular Therapies, which could be the largest biotech acquisition since Pfizer's purchase of Seagen.
The acquisition of Intra-Cellular Therapies would significantly expand JNJ's presence in the neuroscience biotech sector, potentially boosting its growth and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90